Skip to main content
Premium Trial:

Request an Annual Quote

Bate, Fanucci Up, Kailian Out in Millennium s Management Musical Chairs; Don Westmacott and Manzur Durrani Join Quark Biotech; and Others

NEW YORK, July 16 - Don Westmacott has been appointed director of bioassay development and high-throughput screening, and Manzer Durrani has been appointed vice president of pharmaceutics and manufacturing at the new Fremont, Calif., facility of Quark Biotech, the company said today.


Westmacott comes to Quark from Signature Biosciences, where he was director of screening. Prior to his stint at this early-stage proteomics company, Westamacott spent ten years at Roche working in high-throughput screening and cell biology.


Durrani was previously senior director, global R&D at Baxter HealthCare. He was previously director of pharmaceutical formulations and chemistry and director of parental products development at Genzyme-Transgenics division Primedica; and has held positions at Dow Pharmaceutical Sciences, B.F. Goodrich, and Pfizer.


The appointments come just after the privately-held Cleveland, Ohio company announced it was expanding its operations in clinical and business development.


Michael Sweeney has been promoted to general partner of VC Firm InterWest Partners, and will co-lead the company's life sciences team with other general partners Arnold Oronsky and Gil Kliman, the company said July 15.


Sweeney has been a venture partner at InterWest since 2001, and was Entrepeneur in Residence at the Menlo Park, Calif., and Dallas-based firm from 1998 to 2001. Prior to that, Sweeney developed anti-arrhythmia cardiac devices and founded two companies, Ventritex and Epicor Medical.


Currently, Sweeney represents microfluidics company Fluidigm, which InterWest has backed, among other companies.


Kim Blickenstaff has been named to the board of directors of GeneOhm Sciences, the company said July 15.


Blickenstaff is co-founder, president and CEO of diagnostics firm Biosite.


GeneOhm, of San Diego, is developing a SNP detection platform, multi-analyte array-based assays, as well as technology to read and interpret data from these assays.


Joyce Hersh has joined the Boston office of law firm Kirpatrick & Lockhart, the firm said July 14.


Hersh, a life sciences patent prosecution attorney, was previously group leader for the Human Genome Project at the MIT/Whitehead Institute for Genome Research.


Gregory Simon has been named president of the Center for Accelerating Medical Solutions, a new Washington, D.C.-based life sciences branch of the Milken Institute, the think tank said July 14.


Simon was previously a principal at Infotech Strategies, a Washington, DC consulting firm that specializes in health technology, biotech, education technology, and communication technology. Before that, he was CEO of Simon Strategies/Mindbeam, which focuses on biotechnology, health care, and information technology companies. Simon was also the chief domestic advisor to Vice President Al Gore between 1993 and 1997 on economic, science and technology issues.


The Center for Accelerating Medical solutions aims at bringing together those in the life science field with economists, ethicists, and clinicians to evaluate the clinical research process, make policy recommendations, and seek their implementation, according to a statement by the Milkin Institute .


Walter Fredericks has been elected to the board of directors of Matritech, which develops proteomics-based cancer diagnostic products, the Newton, Mass., company said July 10.


Fredericks is the former president and CEO of forensics testing company LifeCodes, which was acquired by Orchid Biosciences in late 2001.  He founded Electronic Instruments International, and was CEO of Cistron Biotechnology, and vice president of Becton Dickinson Laboratory Systems.


Kenneth Bate has been promoted from CFO to executive vice president, head of commercial operations and CFO of Millennium Pharmaceuticals; Marsha Fanucci has been appointed to the newly-created position of vice president of finance and corporate strategy; and Vaughn Kailian will step down from his role in heading up commercial operations at the end of 2003, but will retain his position of vice chairperson and will continue to serve on the company's board of directors, the company said July 10.


The changes in management come just a month after the Cambridge, Mass. firm announced a major restructuring and 600 layoffs by the end of the year.


Bate joined Millennium as CFO in December 2002. He previously was a partner at health care and life sciences investment banking firm JSB Partners. He also worked at Biogen as vice president of finance and then vice president of sales and marketing.


Kailian has been at Millennium since it acquired COR Therapeutics, for which he was president and CEO, in December 2001.


Fanucci joined Millennium in July 2000, as vice president, mergers and acquisitions. Prior to that, Fanucci was vice president of corporate development and strategy at Genzyme and vice president and managing director at Arthur D. Little.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.